{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:12:08Z","timestamp":1793214728450,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recombinant zoster vaccine (RZV) was approved for adults aged \u226550 years in the United States to prevent herpes zoster (HZ) and postherpetic neuralgia (PHN). This study evaluated real-world vaccine effectiveness (VE) of RZV in adults aged \u226550 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort study was conducted at Kaiser Permanente Southern California (KPSC). The exposed cohort included members aged \u226550 years who received 1 or 2 RZV doses April 2018 to December 2020. They were matched 1:4 with unvaccinated individuals by age, sex, and race\/ethnicity, then followed until December 2022. Adjusted VE (aVE) and 95% confidence interval (CI) were estimated via stratified Cox models for 1 dose and 2 doses against HZ (diagnostic codes B02.xx plus antiviral within 7 days) and PHN (chart review for HZ-related pain persisting &amp;gt;3 months). Stratified aVE by demographic characteristics, immunocompromised status, comorbidities, concomitant vaccination, and overall durability were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among N = 102 766 (median age 68 years) who received 2 RZV doses (4 weeks\u20136 months apart), 48 028 (46.7%) had previously received zoster vaccine live; aVE was 73.9% (95% CI: 71.8%\u201375.8%) for HZ and 83.7% (95% CI: 75.1%\u201389.3%) for PHN. VE against HZ was comparable across individuals with concomitant vaccinations and different comorbidities. VE against HZ and PHN remained stable over 4 years post-vaccination. One-dose VE was 60.3% (56.4%\u201363.9%) against HZ and 45.6% (11.4%\u201366.6%) against PHN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Two doses of RZV were effective in preventing HZ and PHN in adults aged \u226550 years, with durable protection. These findings underscore the importance of adhering to the recommended vaccination schedule.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf329","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:48:49Z","timestamp":1750492129000},"page":"e717-e726","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults \u226550 Years in the United States"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-6534","authenticated-orcid":false,"given":"Hung-Fu","family":"Tseng","sequence":"first","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]},{"name":"Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-9266","authenticated-orcid":false,"given":"Lina S","family":"Sy","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-7345","authenticated-orcid":false,"given":"Bradley K","family":"Ackerson","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-3475","authenticated-orcid":false,"given":"Emily","family":"Rayens","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3227-4818","authenticated-orcid":false,"given":"Jun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-2470","authenticated-orcid":false,"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3999-1884","authenticated-orcid":false,"given":"Yanjun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9469-5875","authenticated-orcid":false,"given":"Jennifer H","family":"Ku","sequence":"additional","affiliation":[{"name":"Center for Integrated Health Care Research, Kaiser Permanente Hawaii , Honolulu, Hawaii ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9675-4601","authenticated-orcid":false,"given":"Leticia I","family":"Vega Daily","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-4896","authenticated-orcid":false,"given":"Harpreet S","family":"Takhar","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4349-5885","authenticated-orcid":false,"given":"Jeannie","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A","family":"Cohen","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-1797","authenticated-orcid":false,"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1921-7626","authenticated-orcid":false,"given":"Driss","family":"Oraichi","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8048-5885","authenticated-orcid":false,"given":"Harry","family":"Seifert","sequence":"additional","affiliation":[{"name":"GSK , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-3992","authenticated-orcid":false,"given":"Lei","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"Suppl 1","key":"2026020907375660800_ciaf329-B1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026020907375660800_ciaf329-B2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency","volume":"26","author":"Mueller","year":"2008","journal-title":"Neurol Clin"},{"key":"2026020907375660800_ciaf329-B3","doi-asserted-by":"crossref","first-page":"ofae211","DOI":"10.1093\/ofid\/ofae211","article-title":"Incidence of herpes zoster and postherpetic neuralgia and herpes zoster vaccination uptake in a US administrative claims database","volume":"11","author":"Marcum","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026020907375660800_ciaf329-B4","doi-asserted-by":"crossref","first-page":"e3210","DOI":"10.1093\/cid\/ciaa1185","article-title":"Herpes zoster and postherpetic neuralgia: changing incidence rates from 1994 to 2018 in the United States","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026020907375660800_ciaf329-B5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026020907375660800_ciaf329-B6","author":"European Medicines Agency"},{"key":"2026020907375660800_ciaf329-B7","author":"U.S. Food and Drug Administration"},{"key":"2026020907375660800_ciaf329-B8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026020907375660800_ciaf329-B9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020907375660800_ciaf329-B10","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020907375660800_ciaf329-B11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.1996.03530290060038","article-title":"Evaluating new vaccines for developing countries. Efficacy or effectiveness?","volume":"275","author":"Clemens","year":"1996","journal-title":"JAMA"},{"key":"2026020907375660800_ciaf329-B12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/oxfordjournals.epirev.a036023","article-title":"Assessing vaccine efficacy in the field. Further observations","volume":"10","author":"Orenstein","year":"1988","journal-title":"Epidemiol Rev"},{"key":"2026020907375660800_ciaf329-B13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1086\/652404","article-title":"Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"key":"2026020907375660800_ciaf329-B14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026020907375660800_ciaf329-B15","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.vaccine.2021.05.056","article-title":"Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"2026020907375660800_ciaf329-B16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study","volume":"73","author":"Sun","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026020907375660800_ciaf329-B17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/M23-2023","article-title":"Effectiveness of recombinant zoster vaccine against herpes zoster in a real-world setting","volume":"177","author":"Zerbo","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026020907375660800_ciaf329-B18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US census bureau data","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"key":"2026020907375660800_ciaf329-B19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/bmj.321.7264.778","article-title":"The management of post-herpetic neuralgia","volume":"321","author":"Cunningham","year":"2000","journal-title":"BMJ"},{"key":"2026020907375660800_ciaf329-B20","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1016\/j.vaccine.2023.04.075","article-title":"Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study","volume":"41","author":"Ku","year":"2023","journal-title":"Vaccine"},{"key":"2026020907375660800_ciaf329-B21","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf329\/63550978\/ciaf329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/e717\/63550978\/ciaf329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/6\/e717\/63550978\/ciaf329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:38:05Z","timestamp":1770640685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/6\/e717\/8171839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf329","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2025,6,23]]}}}